Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Quidel to Present at Upcoming Conferences
Quidel to Present at Upcoming Conferences


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy
Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy


Humana Pharmacy, the mail-delivery pharmacy service of Humana Inc. (NYSE: HUM), has won the prestigious 2019 Surescripts White Coat Award, an honor that celebrates healthcare industry leaders

Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek
Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek


For the second year in a row, Humana Inc. (NYSE: HUM) rose to the top as No. 1 in service in its industry, according to Newsweek’s 2020 list of America’s Best Customer Service.



“We’re proud to

Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination


Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be

Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index
Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index


For the third year in a row, Humana Inc. (NYSE: HUM) has achieved top Gold-level recognition in the American Heart Association’s Workplace Health Achievement Index, a science-based assessment that

Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting


Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy and

Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019
Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019


Veeva Systems (NYSE:VEEV) will announce financial results for its third quarter which ended October 31, 2019 after the market close on November 26, 2019. Veeva will host a conference call and

Almirall Makes Shift to Specialty Medicine with Veeva CRM 
Almirall Makes Shift to Specialty Medicine with Veeva CRM 


Veeva Systems (NYSE:VEEV) today announced that Almirall selected multichannel Veeva CRM to deliver seamless customer experience across all channels as it shifts business focus to specialty

Veeva Completes Acquisition of Crossix
Veeva Completes Acquisition of Crossix


Veeva Systems (NYSE:VEEV) today announced it has completed its acquisition of Crossix Solutions. Trusted by more than 200 pharmaceutical brands, Crossix provides privacy-safe U.S. patient data and

Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed
Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed


Waters Corporation (NYSE:WAT) announced today that its ACQUITY™ Advanced Polymer Chromatography™ (APC™) System is the first fully solvent-compatible UltraPerformance Liquid Chromatography

Dexcom Reports Third Quarter 2019 Financial Results
Dexcom Reports Third Quarter 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.



Third Quarter 2019 Highlights:




  • Revenue grew 49% versus the same quarter of

Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/



Dr. Howard Mayer, Executive Vice-President and Head


Agilent Named One of Top 10 Best Workplaces in Singapore
Agilent Named One of Top 10 Best Workplaces in Singapore


Agilent Technologies, Inc. (NYSE: A) today announced it has been named among the top 10 Best Workplaces™ in Singapore for 2019 by the Great Place to Work® (GPTW) Institute. Agilent was selected as

CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
In release dated November 4, 2019, the Piper Jaffray Conference webcast date should read: December 4 (instead of December 3), and the Evercore webcast date should read: December 5 (instead of
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!

Einer der größten Gewinner am US-Aktienmarkt war gestern das Papier von Biogen (WKN: 789617). Grund hierfür waren jedoch nicht in erster Linie die vorgelegten, sehr guten Quartalszahlen, sondern

FMC: Es ist wieder mal Zeit für Skandale!
FMC: Es ist wieder mal Zeit für Skandale!

Dass Aktien von Fresenius Medical Care (WKN: 578580) in der laufenden Woche zu den größten Verlierern im DAX gehören – seit Montag steht ein Minus von -4,26% zu Buche – ist wohl maßgeblich auf

Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc